EA200300286A1 - Агонисты активируемых пероксисомальным пролифератором рецепторов - Google Patents

Агонисты активируемых пероксисомальным пролифератором рецепторов

Info

Publication number
EA200300286A1
EA200300286A1 EA200300286A EA200300286A EA200300286A1 EA 200300286 A1 EA200300286 A1 EA 200300286A1 EA 200300286 A EA200300286 A EA 200300286A EA 200300286 A EA200300286 A EA 200300286A EA 200300286 A1 EA200300286 A1 EA 200300286A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
unsubstituted
substituted
haloalkyl
agonists
Prior art date
Application number
EA200300286A
Other languages
English (en)
Russian (ru)
Inventor
Дон Алиса Брукс
Александр Гленн Годфри
Сара Бет Джоунз
Джеймс Рэй Маккарти
Кристофер Джон Рито
Леонард Ларри Джуниор Уиннероски
Янпинг Ксу
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200300286A1 publication Critical patent/EA200300286A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
EA200300286A 2000-08-23 2001-08-23 Агонисты активируемых пероксисомальным пролифератором рецепторов EA200300286A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
PCT/US2001/022616 WO2002016331A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (1)

Publication Number Publication Date
EA200300286A1 true EA200300286A1 (ru) 2003-08-28

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300286A EA200300286A1 (ru) 2000-08-23 2001-08-23 Агонисты активируемых пероксисомальным пролифератором рецепторов

Country Status (26)

Country Link
US (2) US6930120B2 (cg-RX-API-DMAC10.html)
EP (1) EP1313716B1 (cg-RX-API-DMAC10.html)
JP (1) JP2004506721A (cg-RX-API-DMAC10.html)
KR (1) KR20030027054A (cg-RX-API-DMAC10.html)
CN (1) CN1471517A (cg-RX-API-DMAC10.html)
AT (1) ATE361283T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001284659A1 (cg-RX-API-DMAC10.html)
BR (1) BR0113409A (cg-RX-API-DMAC10.html)
CA (1) CA2418104A1 (cg-RX-API-DMAC10.html)
CY (1) CY1107679T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ2003482A3 (cg-RX-API-DMAC10.html)
DE (1) DE60128239T2 (cg-RX-API-DMAC10.html)
DK (1) DK1313716T3 (cg-RX-API-DMAC10.html)
EA (1) EA200300286A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP034504A (cg-RX-API-DMAC10.html)
ES (1) ES2286137T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0300857A3 (cg-RX-API-DMAC10.html)
IL (1) IL154110A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA03001558A (cg-RX-API-DMAC10.html)
NO (1) NO20030729L (cg-RX-API-DMAC10.html)
NZ (1) NZ523804A (cg-RX-API-DMAC10.html)
PL (1) PL360744A1 (cg-RX-API-DMAC10.html)
PT (1) PT1313716E (cg-RX-API-DMAC10.html)
SK (1) SK1872003A3 (cg-RX-API-DMAC10.html)
WO (1) WO2002016331A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200300570B (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
CA2418134A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
PL374818A1 (en) 2002-07-03 2005-10-31 F.Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
ATE483699T1 (de) * 2002-08-30 2010-10-15 Hoffmann La Roche Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
WO2004024726A1 (en) 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
CA2503117C (en) 2002-11-08 2010-12-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
DE60323130D1 (de) 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
ES2286679T3 (es) * 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
RU2174121C2 (ru) * 1996-08-19 2001-09-27 Джапан Тобакко Инк. Производные пропионовой кислоты и фармацевтическая композиция на их основе
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
CA2418134A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
ECSP034504A (es) 2003-04-25
PL360744A1 (en) 2004-09-20
DE60128239D1 (de) 2007-06-14
ES2286137T3 (es) 2007-12-01
AU2001284659A1 (en) 2002-03-04
NO20030729L (no) 2003-04-02
NZ523804A (en) 2004-09-24
EP1313716A1 (en) 2003-05-28
BR0113409A (pt) 2003-07-01
EP1313716B1 (en) 2007-05-02
US20050245584A1 (en) 2005-11-03
WO2002016331A1 (en) 2002-02-28
JP2004506721A (ja) 2004-03-04
MXPA03001558A (es) 2003-06-06
CN1471517A (zh) 2004-01-28
CZ2003482A3 (cs) 2003-05-14
HUP0300857A2 (hu) 2003-10-28
CY1107679T1 (el) 2013-04-18
DK1313716T3 (da) 2007-08-27
NO20030729D0 (no) 2003-02-14
PT1313716E (pt) 2007-07-11
ZA200300570B (en) 2004-04-21
US6930120B2 (en) 2005-08-16
IL154110A0 (en) 2003-07-31
US7345070B2 (en) 2008-03-18
US20040097590A1 (en) 2004-05-20
DE60128239T2 (de) 2008-01-10
HUP0300857A3 (en) 2007-03-28
SK1872003A3 (en) 2003-07-01
ATE361283T1 (de) 2007-05-15
CA2418104A1 (en) 2002-02-28
KR20030027054A (ko) 2003-04-03

Similar Documents

Publication Publication Date Title
CY1107679T1 (el) Παραγωγα οξαζολυλ-αρυλ προπιονικου οξεος και χρηση αυτων σαν αγωνιστες ppar
ATE368653T1 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
EA200401613A1 (ru) Лекарственное средство для лечения рака
FI935887A0 (fi) Tiazolidindionderivat, deras framstaellning och anvaendning
EP1357115A4 (en) ALKANOIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
PE20000625A1 (es) Derivados de acido oxiiminoalcanoico
RU2006101890A (ru) Производные тиазолилпиперидина в качестве ингибиторов мпб
CA2400141A1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
EA200300305A1 (ru) Альфа-арилэтаноламины и их применение в качестве агонистов бета-адренергических рецепторов
NO991957D0 (no) Nye benzotiofen, benzofuran og indolforbindelser, en fremgangsmÕte ved deres fremstilling og farmas°ytiske sammensetninger inneholdende dem
EA200500087A1 (ru) Производные пиперазина
SE8006365L (sv) Cyklohexankarboxylsyraderivat
EA200300926A1 (ru) Новый способ промышленного синтеза метил дисложного эфира 5-амино-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
AR040123A1 (es) Compuestos tiofeno, antihelminticos e insecticidas
NO20074738L (no) Aktivator for peroksisom-proliferator som aktiverer reseptor delta
EA200300010A1 (ru) Производные 2-аминотиазолина и их применение в качестве ингибиторов no-синтазы
ES531933A0 (es) Un procedimiento para preparar un derivado de imidazolinona
EA200101050A1 (ru) Замещенные бензолактамные соединения
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
AU532634B2 (en) Thiazolyl derivatives
DK272684A (da) Tetrahydro-beta-carbolin-derivater og fremgangsmaade til fremstilling deraf
EA200200462A1 (ru) Производные 2-арилхинолина, их получение и терапевтическое применение
ES391916A1 (es) Un procedimiento de preparar nuevos compuestos de sulfoni- lurea o de sus sales.
HRP20080501T3 (en) Beta-lactams for the treatment of cns disorders
FI935399L (fi) N-substituerade azabicykloheptanderivat samt deras framstaellning och anvaendning